Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287

Gain Therapeutic announces the last healthy subject in the multiple ascending dose, MAD, part of its Phase 1 study has completed the highest planned dose levels. No discontinuations or serious adverse events were reported. After database lock, topline data from this Phase 1, randomized, double-blind, placebo-controlled study is expected to be released in August, and full safety analysis and plasma pharmacokinetics are expected to be presented at a future congress. “The successful completion of the SAD/MAD in 72 healthy subjects with no serious adverse events or discontinuations related to adverse events and the ability to achieve therapeutic plasma levels with oral dosing further confirm our belief in GT-02287’s potential to be a transformative therapy for Parkinson’s disease patients,” commented Gain’s Executive Chairman, Khalid Islam, Ph.D. “We remain on track with our recent guidance and look forward to continuing to advance GT-02287 through clinical development and initiating a trial in Parkinson’s disease patients by Q4 2024.”